Abstract | OBJECTIVES: METHODS: We treated 24 chemotherapy-naive patients with unresectable pancreatic cancer. To prevent gastroduodenal injury from 5-FU infusion, the catheter was placed to allow the distribution of 5-FU to the pancreatic tumor and the liver after occlusion of the gastric and pancreaticoduodenal arteries. 5-FU was administered at a dose of 250 mg/d on days 1 to 5 every week as a continuous arterial infusion. Gemcitabine was infused intravenously at a dose of 1000 mg once weekly for 3 consecutive weeks of every 4 weeks. RESULTS: The partial response rate was 20.8% (5 of 24), although there was no case of complete response. Fourteen cases (58.3%) were stable disease, and 5 cases (20.8%) were progressive disease. The most common toxicities were hematological and gastrointestinal events. No patients died of adverse effects using this chemotherapy. Gastric and/or duodenal ulcers occurred because of 5-FU intra-arterial infusion. Catheter-related cholangitis occurred in patients with biliary drainage for obstructive jaundice. Median survival time was 14 months, with a 50.9% 1-year survival rate, although patients with performance status 2 and multiple organ metastases had a poor prognosis. CONCLUSIONS:
|
Authors | Hiroshi Takamori, Keiichiro Kanemitsu, Tatsuya Tsuji, Hiroshi Tanaka, Akira Chikamoto, Osamu Nakahara, Takehisa Hiraoka, Osamu Ikeda, Koichi Kudo, Masanori Imuta, Yasuyuki Yamashita |
Journal | Pancreas
(Pancreas)
Vol. 30
Issue 3
Pg. 223-6
(Apr 2005)
ISSN: 1536-4828 [Electronic] United States |
PMID | 15782098
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Antimetabolites, Antineoplastic
- Deoxycytidine
- Fluorouracil
- Gemcitabine
|
Topics |
- Adenocarcinoma
(drug therapy)
- Adult
- Aged
- Antimetabolites, Antineoplastic
(administration & dosage, adverse effects)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects)
- Deoxycytidine
(administration & dosage, adverse effects, analogs & derivatives)
- Female
- Fluorouracil
(administration & dosage, adverse effects)
- Humans
- Infusions, Intra-Arterial
- Male
- Middle Aged
- Pancreatic Neoplasms
(drug therapy)
- Survival Rate
- Treatment Outcome
- Gemcitabine
|